Garry A. Neil's most recent trade in Avalo Therapeutics Inc was a trade of 64,866 Common Stock done . Disclosure was reported to the exchange on March 28, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Avalo Therapeutics Inc | Garry A. Neil | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 64,866 | 112,006 | - | - | Common Stock | |
| Avalo Therapeutics Inc | Garry A. Neil | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 64,866 | 64,867 | - | - | Restricted Stock Units | |
| Avalo Therapeutics Inc | Garry A. Neil | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.89 per share. | 28 Mar 2026 | 21,892 | 90,114 | - | 13.9 | 304,080 | Common Stock |
| Celldex Therapeutics Inc | Garry A. Neil | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 16,500 | 16,500 | - | - | Non-Qualified Stock Option (right to buy) | |
| Avalo Therapeutics Inc | Garry A. Neil | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 64,867 | 129,733 | - | - | Restricted Stock Units | |
| Avalo Therapeutics Inc | Garry A. Neil | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 64,867 | 64,927 | - | - | Common Stock | |
| Avalo Therapeutics Inc | Garry A. Neil | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.46 per share. | 28 Mar 2025 | 17,787 | 47,140 | - | 8.5 | 150,478 | Common Stock |
| Avalo Therapeutics Inc | Garry A. Neil | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 411,000 | 411,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Garry A. Neil | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 500,400 | 500,400 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Garry A. Neil | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 194,600 | 194,600 | - | - | Restricted Stock Units | |
| Celldex Therapeutics Inc | Garry A. Neil | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 16,500 | 16,500 | - | - | Non-Qualified Stock Option (right to buy) | |
| Celldex Therapeutics Inc | Garry A. Neil | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 11,300 | 11,300 | - | - | Non-Qualified Stock Option (right to buy) | |
| Avalo Therapeutics Inc | Garry A. Neil | Director, CEO and Chairman of the Board | Purchase of securities on an exchange or from another person at price $ 3.42 per share. | 09 Jun 2023 | 4,000 | 13,220 | - | 3.4 | 13,680 | Common Stock |
| Zura Bio Ltd (Class A) | Garry A. Neil | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 7,652 | 7,652 | - | - | Employee Share Option (Right to Buy) | |
| Avalo Therapeutics Inc | Garry A. Neil | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Garry A. Neil | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Garry A. Neil | Director, CEO and Chairman of the Board | Purchase of securities on an exchange or from another person at price $ 4.42 per share. | 09 Dec 2022 | 2,083 | 9,220 | - | 4.4 | 9,207 | Common Stock |
| Avalo Therapeutics Inc | Garry A. Neil | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2022 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Celldex Therapeutics Inc | Garry A. Neil | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 27,200 | 27,200 | - | - | Non-Qualified Stock Option (right to buy) | |
| Avalo Therapeutics Inc | Garry A. Neil | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 1,000,000 | 1,000,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Garry A. Neil | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 1.57 per share. | 10 Dec 2021 | 4,267 | 85,639 | - | 1.6 | 6,699 | Common Stock |
| Avalo Therapeutics Inc | Garry A. Neil | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 2.28 per share. | 10 Jun 2021 | 3,692 | 81,372 | - | 2.3 | 8,418 | Common Stock |